Clinical Trials · NCT04103034

A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers

CompletedPhase 1Desmopressin (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Band Therapeutics
Enrollment
112
Start date
Oct 2019
Locations
1 site, Austria
Primary endpoint
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
View Desmopressin compound reference